By Tapan Panchal

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that a phase III study to assess the efficacy of an investigational vaccine for the prevention of shingles has met its primary objective.

Analysis showed that the HZ/su vaccine reduced the risk of shingles by 97.2% in adults aged 50 years and older, compared with placebo.

Shingles is a type of rash that develops on one side of the human body caused by the chickenpox virus.

At 1209 GMT, shares of Glaxo were trading 0.5% higher at 1,354 pence.

-Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.